UBS Asset Management Americas Inc. lessened its holdings in shares of Humana Inc (NYSE:HUM) by 5.3% during the 4th quarter, Holdings Channel reports. The firm owned 724,263 shares of the insurance provider’s stock after selling 40,220 shares during the period. UBS Asset Management Americas Inc.’s holdings in Humana were worth $179,668,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in HUM. Sterling Capital Management LLC acquired a new stake in Humana during the 2nd quarter worth $253,000. WFG Advisors LP boosted its stake in Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the last quarter. Shell Asset Management Co. boosted its stake in Humana by 442.6% during the 3rd quarter. Shell Asset Management Co. now owns 69,504 shares of the insurance provider’s stock worth $9,056,000 after purchasing an additional 56,695 shares during the last quarter. PGGM Investments acquired a new stake in Humana during the 3rd quarter worth $41,767,000. Finally, Mutual of America Capital Management LLC boosted its stake in Humana by 6.2% during the 3rd quarter. Mutual of America Capital Management LLC now owns 30,402 shares of the insurance provider’s stock worth $7,407,000 after purchasing an additional 1,762 shares during the last quarter. 94.13% of the stock is currently owned by institutional investors.
In other Humana news, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the transaction, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the transaction, the vice president now directly owns 11,557 shares in the company, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. Insiders sold 10,115 shares of company stock worth $2,501,627 in the last ninety days. 0.80% of the stock is currently owned by corporate insiders.
Humana Inc (HUM) opened at $269.00 on Friday. Humana Inc has a 1 year low of $203.36 and a 1 year high of $293.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.61. The company has a market cap of $37,035.65, a PE ratio of 23.01, a price-to-earnings-growth ratio of 1.46 and a beta of 0.93.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The company had revenue of $13.19 billion for the quarter, compared to analysts’ expectations of $13.14 billion. During the same quarter in the prior year, the company posted $2.34 earnings per share. Humana’s revenue for the quarter was up 2.4% compared to the same quarter last year. equities research analysts forecast that Humana Inc will post 13.86 EPS for the current fiscal year.
Humana declared that its board has approved a share buyback plan on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to reacquire shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a $0.50 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.74%. This is a boost from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio is presently 9.59%.
Several brokerages have issued reports on HUM. Deutsche Bank lifted their target price on shares of Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. JPMorgan Chase & Co. lifted their target price on shares of Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a research note on Monday, February 12th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $250.00 target price on shares of Humana in a research note on Wednesday, February 7th. Oppenheimer lifted their target price on shares of Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Finally, Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $294.00 target price on the stock in a research note on Monday, February 12th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $270.47.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.